About bendamust ine hydrochlo
Alkylating chemotherapy medicine
Used for
- Chronic lymphocytic leukaemia
- Non-Hodgkin lymphoma
- Multiple myeloma, with other medicines
Usual adult dose
Common regimens use 90–120 mg/m² intravenously on days 1 and 2, repeated every 3–4 weeks; dose varies by cancer and regimen.
Common side effects
- Low blood cell counts and infection
- Nausea, vomiting, diarrhoea, or constipation
- Tiredness and weakness
- Infusion reactions or skin rash
Important warnings
- Can cause severe infection, bleeding, or anaemia from low blood counts.
- Rarely causes severe skin reactions or tumour lysis syndrome.
- Can harm an unborn baby; effective contraception is needed during treatment.
- Requires monitoring of blood counts, liver function, and kidney function.
Pregnancy
Avoid during pregnancy; bendamustine may harm the developing baby. Contraception is recommended during treatment and for a period afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one week after the final dose.
Interactions
- Medicines that suppress bone marrow can increase blood-count problems.
- Some medicines affecting CYP1A2 may change bendamustine exposure.
- Live vaccines may cause infection during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.